Eppley Institute Adopts DNASTAR Software
News Jul 04, 2013
DNASTAR has announced that the Eppley Institute for Research in Cancer at the University of Nebraska Medical Center has chosen DNASTAR Lasergene software as its sequence assembly and analysis software platform for its faculty, staff and students.
Dr. Adam Karpf, Associate Professor at the Institute, said, “Many of our researchers have used Lasergene for years and been extremely satisfied with it. DNASTAR made us an attractive offer to provide access to their software to all of our scientists, staff and students. We took advantage of the opportunity to allow our team to have access to strong molecular biology software on an unlimited basis. This arrangement will help support our success and growth for years to come.”
Tom Schwei, Vice President and General Manager of DNASTAR, stated, “This site license provides a uniform structure that will support the Institute in all of its endeavors. As we continue to develop our software to meet emerging cancer research needs, all faculty, staff and students at the Institute will benefit by having access to the most recent developments in our products. We appreciate the trust placed in our tools and company by the staff of the Institute and we look forward to continuing to meet their sequence assembly and analysis software needs in the future.”
Financial terms of the arrangement were not disclosed.
Data Storage at the Single Molecule LevelNews
A research team from Kiel University has now not only managed to successfully place a new class of spin-crossover molecules onto a surface, but they have also used interactions which were previously regarded as obstructive to improve the molecule's storage capacity.READ MORE
Public Resource of Cellular Effects of Drugs and Genes Boosts Drug Discovery and Offers Insights Into Protein FunctionNews
Researchers have taken the Connectivity Map — a widely used resource of tools and data — to new heights with a massively scaled-up version including more cell types, more perturbations, and more types of data, including proteomic and cellular imaging data. For this new platform, the researchers have also improved its accessibility for the scientific community, enabling studies of small molecule and gene function and informing clinical trials.READ MORE